E
UTHR icon

Ergoteles’s United Therapeutics UTHR Stock Holding History

Ergoteles’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,414
Closed -$393K – 1775
2022
Q4 		$393K Sell
1,414
-2,110
-60% -$533K 0.01% 800
2022
Q3 		$738K Buy
+3,524
New +$788K 0.03% 614
2020
Q4 		– Sell
-3,625
Closed -$366K – 924
2020
Q3 		$366K Buy
+3,625
New +$398K 0.05% 288

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Ergoteles's UTHR Position: Q1 2023 in Review

Ergoteles sold out of United Therapeutics (UTHR) in Q1 2023, closing a stake of 1,414 shares — an estimated $393K sold.

Ergoteles first reported a position in UTHR in Q3 2020 and held it in 3 quarters. The position peaked at $738K in Q3 2022. 505 funds tracked by Wall St. Rank hold UTHR as of Q1 2023.

  • Ergoteles reported no remaining United Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Ergoteles sold 1,414 United Therapeutics shares in Q1 2023, an estimated $393K.
  • Ergoteles first reported a position in United Therapeutics in Q3 2020 and held it in 3 quarters.
  • Ergoteles's United Therapeutics position peaked at $738K in Q3 2022.
  • 505 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.